Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Summary

It's a single arm, open label prospective study, in which the safety and efficacy of autologous CAR-T are evaluated in refractory/relapsed B cell lymphoma patients. Abbreviation: CAR-T: Chimeric Antigen Receptor T-Cell Immunotherapy.

Timeline

Start

2017-09-15

Primary completion

2019-01-13

Completion

2019-07-30

Drugs

Indications